Core Insights - Calidi Biotherapeutics, Inc. has formed a Scientific Advisory Board (SAB) to enhance the development of its RedTail platform and advance its lead candidate CLD-401 into clinical trials [1][2][4] Company Overview - Calidi Biotherapeutics is a clinical-stage biotechnology company focused on developing targeted genetic medicines using its proprietary RedTail platform, which employs an engineered enveloped oncolytic virus for systemic delivery to metastatic sites [18][19] Scientific Advisory Board Formation - The SAB consists of leading industry and academic researchers with extensive experience in drug development, aimed at guiding the efficient development of CLD-401 [1][4] - Founding members include: - Mace L. Rothenberg, MD, with over 30 years in drug development and a history of leading clinical development at Pfizer [4][6] - Dmitriy Zamarin, MD, PhD, a leader in virotherapy for cancer and a member of the Icahn Genomics Institute [7][9] - John Wrangle, MD, MPH, an expert in IL-15-based treatment for metastatic cancer [10][12] - David T. Curiel, MD, PhD, recognized for his work in cancer immunotherapy and virotherapy [14][16] RedTail Platform and CLD-401 - The RedTail platform utilizes a genetically engineered vaccinia virus designed to overexpress CD55, allowing for targeted delivery of genetic medicine to disease sites while avoiding immune clearance [2][3] - CLD-401 is designed to target metastatic sites, replicate in tumor cells, and induce immune responses through the expression of IL-15 superagonist in the tumor microenvironment [3][19]